Skip to main
PHGE

BiomX Inc. (PHGE) Stock Forecast & Price Target

BiomX Inc. (PHGE) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BiomX Inc. is demonstrating a robust outlook amid favorable clinical trial results for its therapeutic candidates, BX211 and BX011, with significant improvements noted across multiple parameters related to diabetic foot osteomyelitis and chronic pulmonary infections. Positive feedback from the FDA regarding the advancement of BX011 into a Phase 2a study underscores the potential for enhanced efficacy in treating conditions like diabetic foot infections and suggests a promising regulatory pathway. The company’s innovative BOLT platform, combined with ongoing clinical advancements, suggests opportunities for higher market penetration and a broader indication base, contributing positively to BiomX's future financial performance.

Bears say

BiomX Inc. faces significant challenges that have led to a negative outlook on its stock, primarily due to investor sentiment surrounding its clinical trial results. The statistical significance of key endpoints was a concern, particularly as some metrics, such as the week 13 PAR, narrowly missed the conventional threshold, signaling potential issues in the efficacy of its products. Additionally, risks related to failed clinical trials, difficulties in securing adequate funding, and the possibility of dilutive capital raises further contribute to a foreboding financial outlook for the company.

BiomX Inc. (PHGE) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BiomX Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BiomX Inc. (PHGE) Forecast

Analysts have given BiomX Inc. (PHGE) a Strong Buy based on their latest research and market trends.

According to 1 analysts, BiomX Inc. (PHGE) has a Strong Buy consensus rating as of Jan 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BiomX Inc. (PHGE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.